Giampaolo Tortora

List of Publications by Year in Descending Order

78 papers	12,651 citations	35 h-index	83 g-index
83 ext. papers	15,027 ext. citations	10.2 avg, IF	5.77 L-index

#	Paper	IF	Citations
78	Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations.. *Journal of Clinical Oncology*, **2022**, 40, 349-349	2.2	
77	Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).. *Journal of Clinical Oncology*, **2022**, 40, TPS407-TPS407	2.2	
76	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. *European Journal of Cancer*, **2021**, 152, 155-164	7.5	5
75	A Novel Pathogenic Variant in an Italian Woman with Gallbladder Cancer. *Genes*, **2021**, 12,	4.2	0
74	Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer **2021**, 9,		4
73	Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response.. *Frontiers in Medicine*, **2021**, 8, 793144	4.9	1
72	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 308	5.7	5
71	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. *Frontiers in Oncology*, **2020**, 10, 567289	5.3	3
70	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
69	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. *Cancer Research*, **2019**, 79, 4315-4323	12.1	4
68	Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. *New England Journal of Medicine*, **2019**, 381, 317-327	59.2	826
67	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. *Journal of Thoracic Oncology*, **2019**, 14, 1651-1661	8.9	44
66	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. *Scientific Reports*, **2019**, 9, 12286	4.9	15
65	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. *Mediators of Inflammation*, **2019**, 2019, 7652014	4.3	21
64	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. *Immunotherapy*, **2019**, 11, 921-930	3.8	5
63	The development of PARP as a successful target for cancer therapy. *Expert Review of Anticancer Therapy*, **2018**, 18, 161-175	3.5	12
62	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. *Scientific Reports*, **2018**, 8, 7119	4.9	25

61	Do immune checkpoint inhibitors need new studies methodology?. *Journal of Thoracic Disease*, **2018**, 10, S1564-S1580	2.6	35
60	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. *Seminars in Oncology*, **2018**, 45, 176-180	5.5	3
59	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. *JAMA Oncology*, **2018**, 4, 1543-1552	13.4	380
58	Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*, **2017**, 543, 65-71	50.4	482
57	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. *Expert Review of Molecular Diagnostics*, **2017**, 17, 1055-1069	3.8	19
56	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130
55	Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. *Cancer Discovery*, **2016**, 6, 821-3	24.4	5
54	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. *Oncologist*, **2016**, 21, 283-91	5.7	35
53	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
52	Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*, **2015**, 518, 495-501	50.4	1579
51	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. *PLoS ONE*, **2015**, 10, e0130142	3.7	339
50	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. *Translational Lung Cancer Research*, **2015**, 4, 704-12	4.4	7
49	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. *Translational Lung Cancer Research*, **2015**, 4, 721-7	4.4	22
48	High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. *BMC Cancer*, **2014**, 14, 851	4.8	30
47	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. *Expert Opinion on Drug Safety*, **2014**, 13, 535-49	4.1	22
46	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. *Critical Reviews in Oncology/Hematology*, **2014**, 90, 135-45	7	11
45	Reporting tumor molecular heterogeneity in histopathological diagnosis. *PLoS ONE*, **2014**, 9, e104979	3.7	34
44	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. *Oncotarget*, **2014**, 5, 2839-52	3.3	134

43	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. *Expert Opinion on Drug Discovery*, **2013**, 8, 1381-97	6.2	6
42	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, **2013**, 45, 1470-1473	36.3	464
41	Rationale and clinical use of multitargeting anticancer agents. *Current Opinion in Pharmacology*, **2013**, 13, 536-42	5.1	27
40	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. *Proteomics*, **2013**, 13, 866-77	4.8	20
39	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. *Frontiers in Pharmacology*, **2013**, 4, 56	5.6	66
38	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *Journal of Clinical Oncology*, **2012**, 30, 3002-11	2.2	193
37	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature*, **2012**, 491, 399-405	36.4	1427
36	True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. *PLoS ONE*, **2012**, 7, e49689	3.7	10
35	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. *Experimental and Therapeutic Medicine*, **2011**, 2, 449-455	2.1	3
34	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. *Endocrine-Related Cancer*, **2011**, 18, 1-11	5.7	52
33	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. *Clinical Cancer Research*, **2011**, 17, 6531-41	12.9	42
32	Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. *Journal of Biological Chemistry*, **2010**, 285, 6563-72	5.4	19
31	EGFR-Directed Monoclonal Antibodies **2010**, 407-436		
30	A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. *Clinical Cancer Research*, **2009**, 15, 6921-30	12.9	32
29	EGFR antagonists in cancer treatment. *New England Journal of Medicine*, **2008**, 358, 1160-74	59.2	1570
28	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. *Nature Clinical Practice Oncology*, **2008**, 5, 521-30		94
27	EGFR-targeting agents in oncology. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 889-901	6.8	16
26	Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. *Clinical Cancer Research*, **2008**, 14, 5069-80	12.9	127

25	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. *Journal of Cellular Physiology*, **2008**, 216, 698-707	7	29
24	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. *Critical Reviews in Oncology/Hematology*, **2008**, 65, 200-11	7	50
23	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. *Differentiation*, **2007**, 75, 788-99	3.5	65
22	Mechanisms of resistance to EGFR inhibitors. *Targeted Oncology*, **2007**, 2, 31-37	5	5
21	Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. *Cancer Research*, **2007**, 67, 6351-9	10.1	59
20	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12468-73	11.5	56
19	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. *Molecular Cancer Therapeutics*, **2007**, 6, 3091-100	6.1	9
18	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. *Current Cancer Therapy Reviews*, **2007**, 3, 117-126	0.4	
17	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. *Current Cancer Therapy Reviews*, **2007**, 3, 276-283	0.4	
16	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. *Drug Resistance Updates*, **2007**, 10, 81-100	23.2	62
15	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. *Journal of Cellular Physiology*, **2006**, 208, 344-53	7	54
14	Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. *Clinical Cancer Research*, **2006**, 12, 577-83	12.9	75
13	Key cancer cell signal transduction pathways as therapeutic targets. *European Journal of Cancer*, **2006**, 42, 290-4	7.5	118
12	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. *Clinical Cancer Research*, **2005**, 11, 4741-8	12.9	271
11	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. *Endocrine-Related Cancer*, **2005**, 12, 1051-8	5.7	30
10	Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. *Clinical Cancer Research*, **2005**, 11, 5639-44	12.9	79
9	Angiogenesis: a target for cancer therapy. *Current Pharmaceutical Design*, **2004**, 10, 11-26	3.3	61
8	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. *Clinical Cancer Research*, **2004**, 10, 784-93	12.9	309

7	Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. *Annals of the New York Academy of Sciences*, **2003**, 1002, 236-43	6.5	20
6	Antisense strategies targeting protein kinase C: preclinical and clinical development. *Seminars in Oncology*, **2003**, 30, 26-31	5.5	32
5	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. *Clinical Prostate Cancer*, **2003**, 2, 50-7		49
4	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. *Clinical Cancer Research*, **2003**, 9, 1546-56	12.9	229
3	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. *Clinical Cancer Research*, **2002**, 8, 3438-44	12.9	313
2	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. *Cancer Research*, **2002**, 62, 7284-90	10.1	425
1	Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. *International Journal of Cancer*, **1993**, 53, 438-43	7.5	41